(E)-2,4,4',5-tetramethoxystilbene | 129047-44-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-2,4,4',5-tetramethoxystilbene
• 英文别名: 1,2,4-trimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene
• CAS: 129047-44-5
• 化学式: C₁₈H₂₀O₄
• 分子量: 300.354
• InChiKey: AKQHUTDDOKTMAH-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对甲氧基苯乙酸 在 哌啶 、 喹啉 、 copper(II) carbonate 作用下， 反应 22.0h， 生成 (E)-2,4,4',5-tetramethoxystilbene
  参考文献：
  名称：

  Anjaneyulu; Rani; Mallavadhani, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 3, p. 219 - 223

  摘要：

  DOI：

文献信息

• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• Substituted <i>trans</i>-Stilbenes, Including Analogues of the Natural Product Resveratrol, Inhibit the Human Tumor Necrosis Factor Alpha-Induced Activation of Transcription Factor Nuclear Factor KappaB
  作者：Justin J. Heynekamp、Waylon M. Weber、Lucy A. Hunsaker、Amanda M. Gonzales、Robert A. Orlando、Lorraine M. Deck、David L. Vander Jagt

  DOI：10.1021/jm060630x

  日期：2006.11.30

  The transcription factor nuclear factor kappaB (NF-kappa B), which regulates expression of numerous antiinflammatory genes as well as genes that promote development of the prosurvival, antiapoptotic state is up-regulated in many cancer cells. The natural product resveratrol, a polyphenolic trans-stilbene, has numerous biological activities and is a known inhibitor of activation of NF-kappa B, which may account for some of its biological activities. Resveratrol exhibits activity against a wide variety of cancer cells and has demonstrated activity as a cancer chemopreventive against all stages, i.e., initiation, promotion, and progression. The biological activities of resveratrol are often ascribed to its antioxidant activity. Both antioxidant activity and biological activities of analogues of resveratrol depend upon the number and location of the hydroxy groups. In the present study, phenolic analogues of resveratrol and a series of substituted trans-stilbenes without hydroxy groups were compared with resveratrol for their abilities to inhibit the human tumor necrosis factor alpha-induced (TNF-alpha) activation of NF-kappa B, using the Panomics NF-kappa B stable reporter cell line 293/NF-kappa B-luc. A series of 75 compounds was screened to identify substituted trans-stilbenes that were more active than resveratrol. Dose-response studies of the most active compounds were carried out to obtain IC50 values. Numerous compounds were identified that were more active than resveratrol, including compounds that were devoid of hydroxy groups and were 100-fold more potent than resveratrol. The substituted trans-stilbenes that were potent inhibitors of the activation of NF-kappa B generally did not exhibit antioxidant activity. The results from screening were confirmed using BV-2 microglial cells where resveratrol and analogues were shown to inhibit LPS-induced COX-2 expression.
• ANJANEYULU, A. S. R.;RANI, G. SUDHA;MALLAVADHANI, U. V.;MURTHY, Y. L. N., INDIAN J. CHEM. A, 29,(1990) N, C. 219-223
  作者：ANJANEYULU, A. S. R.、RANI, G. SUDHA、MALLAVADHANI, U. V.、MURTHY, Y. L. N.

  DOI：——

  日期：——
• ANJANEYULU, A. S. R.;RANI, G. SUDHA;MALLAVADHANI, U. V.;MURTHY, Y. L. N., INDIAN J. CHEM. B, 29,(1990) N, C. 219-223
  作者：ANJANEYULU, A. S. R.、RANI, G. SUDHA、MALLAVADHANI, U. V.、MURTHY, Y. L. N.

  DOI：——

  日期：——
• SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
  申请人：STC. UNM

  公开号：US20130178536A1

  公开（公告）日：2013-07-11

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.